Charles Schwab
BEAM icon

Charles Schwab’s Beam Therapeutics BEAM Stock Holding History

Charles Schwab’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.4M Buy
885,902
+77,466
+10% +$2.34M ﹤0.01% 1563
2026
Q1 		$19.3M Sell
808,436
-26,359
-3% -$731K ﹤0.01% 1769
2025
Q4 		$23.1M Sell
834,795
-6,415
-0.8% -$164K ﹤0.01% 1659
2025
Q3 		$20.4M Buy
841,210
+66,359
+9% +$1.32M ﹤0.01% 1723
2025
Q2 		$13.2M Sell
774,851
-1,594
-0.2% -$27.8K ﹤0.01% 1883
2025
Q1 		$15.2M Buy
776,445
+127,500
+20% +$3.34M ﹤0.01% 1763
2024
Q4 		$16.1M Buy
648,945
+19,453
+3% +$496K ﹤0.01% 1806
2024
Q3 		$15.4M Buy
629,492
+36,226
+6% +$936K ﹤0.01% 1834
2024
Q2 		$13.9M Buy
593,266
+13,994
+2% +$344K ﹤0.01% 1876
2024
Q1 		$19.1M Buy
579,272
+8,036
+1% +$250K ﹤0.01% 1638
2023
Q4 		$15.5M Buy
571,236
+29,826
+6% +$741K ﹤0.01% 1744
2023
Q3 		$13M Buy
541,410
+39,990
+8% +$1.07M ﹤0.01% 1772
2023
Q2 		$16M Buy
501,420
+37,806
+8% +$1.23M ﹤0.01% 1645
2023
Q1 		$14.2M Buy
463,614
+2,460
+0.5% +$97.1K ﹤0.01% 1702
2022
Q4 		$18M Buy
461,154
+9,247
+2% +$414K 0.01% 1514
2022
Q3 		$21.5M Buy
451,907
+54,458
+14% +$3.11M 0.01% 1313
2022
Q2 		$15.4M Buy
397,449
+26,533
+7% +$1.05M 0.01% 1584
2022
Q1 		$21.3M Buy
370,916
+23,092
+7% +$1.51M 0.01% 1493
2021
Q4 		$27.7M Buy
347,824
+14,304
+4% +$1.22M 0.01% 1327
2021
Q3 		$29M Buy
333,520
+82,078
+33% +$8.25M 0.01% 1256
2021
Q2 		$32.4M Buy
251,442
+31,750
+14% +$2.53M 0.01% 1193
2021
Q1 		$17.6M Buy
219,692
+16,010
+8% +$1.52M 0.01% 1627
2020
Q4 		$16.6M Buy
203,682
+32,171
+19% +$1.58M 0.01% 1531
2020
Q3 		$4.22M Buy
171,511
+88,909
+108% +$2.21M ﹤0.01% 2148
2020
Q2 		$2.31M Buy
82,602
+56,597
+218% +$1.22M ﹤0.01% 2374
2020
Q1 		$469K Buy
+26,005
New +$565K ﹤0.01% 2738

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Charles Schwab's BEAM Position: Q2 2026 in Review

Charles Schwab increased its Beam Therapeutics (BEAM) stake by 9.6% in Q2 2026, buying an estimated $2.34M and bringing the position to 885,902 shares worth $30.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1563.

Charles Schwab first reported a position in BEAM in Q1 2020 and has held it in 26 quarters since. The position peaked at $32.4M in Q2 2021. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Charles Schwab held 885,902 shares of Beam Therapeutics worth $30.4M as of Q2 2026.
  • Charles Schwab bought 77,466 Beam Therapeutics shares in Q2 2026, an estimated $2.34M.
  • Beam Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #1563 holding.
  • Charles Schwab first reported a position in Beam Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • Charles Schwab's Beam Therapeutics position peaked at $32.4M in Q2 2021.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.